SynDevRx, Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer (NCT05455619) | SynDevRx, Inc. | 2022-08-26 |
Track SynDevRx, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.